This study tests whether a medicine called ixazomib is safe for people living with HIV, and whether it can wake up HIV that is hiding in the body so the immune system and treatment can reach it.
HIV can stay hidden inside cells even when antiretroviral therapy (ART) keeps the virus under control. These hidden cells are called the HIV reservoir, and they are the reason HIV is not cured by ART alone. Laboratory research suggests ixazomib may reactivate hidden HIV and also help kill the cells that carry it. Ixazomib is already approved to treat a cancer called multiple myeloma and has been given to a smaller group of people with HIV in an earlier study.
About 45 adults with HIV that is well controlled on ART will take part. Participants are assigned by chance to take either ixazomib or a placebo - a capsule with no active medicine - one capsule by mouth once a week for a total of 25 doses. Two out of every three participants receive ixazomib and one out of three receives placebo. Neither participants nor the study staff know which one a participant is taking.
Everyone continues their own HIV treatment throughout the study.
Participation lasts about 7 months: 24 weeks of weekly capsules and 4 more weeks of follow-up after the last dose. Participants come to the clinic for about 14 visits, and take their capsule 24 to 36 hours before each visit so blood samples can show the effect of the dose.
The main purposes of the study are to evaluate whether ixazomib is safe and tolerable, and to measure whether it increases the very small amounts of HIV in the blood compared with placebo. The study also measures the size of the HIV reservoir and how the immune system responds.

Start Date23 Nov 2026

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

[+1]

CTR20262598

/ RecruitingNot Applicable

枸橼酸伊沙佐米胶囊人体生物等效性研究

[Translation] Human bioequivalence study of ixazomib citrate capsules

以山东新时代药业有限公司的枸橼酸伊沙佐米胶囊为受试制剂，Takeda Pharma A/S持证的枸橼酸伊沙佐米胶囊（Ninlaro®/恩莱瑞®）为参比制剂，考察两制剂在空腹状态下单次给药吸收速度和程度的差异，评价两制剂是否生物等效，并评价两制剂在多发性骨髓瘤患者中的安全性。

[Translation]

Using ixazomib citrate capsules from Shandong New Era Pharmaceutical Co., Ltd. as the test formulation and ixazomib citrate capsules (Ninlaro®/恩莱瑞®) certified by Takeda Pharma A/S as the reference formulation, this study investigated the differences in absorption rate and extent of the two formulations under fasting conditions after a single dose, evaluated their bioequivalence, and assessed their safety in patients with multiple myeloma.

Start Date25 Aug 2026

Sponsor / Collaborator

Shandong New Time Pharmaceutical Co. Ltd.

CTRI/2026/05/111359

/ Not yet recruitingNot Applicable

An Open-Label, Multicenter, Randomized, Two Treatment, Parallel, Single-Dose, Bioequivalence Study of Test Product Ixazomib Citrate Capsule 4 mg of Natco Pharma Limited, India with Reference Product NINLARO (Ixazomib Citrate) Capsule 4 mg of Takeda Pharmaceuticals America, Inc., Lexington, MA 02421 in Adult Patients with Multiple Myeloma under Fasting Condition. - NIL

Start Date10 Jun 2026

Sponsor / Collaborator

NATCO Pharma Ltd.

[+1]

100 Clinical Results associated with Ixazomib citrate

100 Translational Medicine associated with Ixazomib citrate

100 Patents (Medical) associated with Ixazomib citrate

963

Literatures (Medical) associated with Ixazomib citrate

01 Nov 2026·JOURNAL OF MOLECULAR GRAPHICS & MODELLING

A multi-Level Study of 20S proteasome inhibitors: an integrated approach combining chemistry and Modelling

Article

Author: Bouachrine, Mohammed ; Sbai, Abdelouahid ; El Allali, Achraf ; Sekkate, Chakib ; Esslali, Soukaina ; Guenoun, Farhate ; Liman, Wissal ; Ouabane, Mohamed ; Tabti, Kamal ; Lakhlifi, Tahar

In view of the important role of 20S proteasome inhibitors in the treatment of multiple myeloma, a 2D-QSAR study was developed using the Monte Carlo approach for 41 peptide boronic acids (PBA) characterised by the CT-L activity of the human 20S proteasome. The QSAR models were generated using six target functions: TF₀, TF_1, TF_2, TF_3, TF₄ and TF₅. Among twenty-four models QSAR developed, the best (model-23 using split-1) was selected based on important statistical performance. Subsequently, the structural fragments responsible for the enhancement of CT-L activity were identified and used to propose new potent inhibitors. Covalent molecular docking was performed for the designed molecules and the reference drug Ixazomib using two human 20S proteasome proteins. All of these inhibitors showed significant binding affinity values, characterised by the formation of a covalent bond between the boron atom of the ligands and the oxygen atom of the threonine residue in position-1. These inhibitors showed good predicted ADMET properties. Two designed inhibitors, P-05 and P-07, were selected to perform MD simulations for 200 ns and to calculate the free binding energy on the two proteins. Finally, the synthesis pathway for P-05 and P-07 was proposed.

01 Oct 2026·BRITISH JOURNAL OF HAEMATOLOGY

Clinical trials portfolio and regulatory outcomes of ixazomib in multiple myeloma: A systematic review and meta‐analysis

Article

Author: Utzman, Payton ; Al Hadidi, Samer ; Cliff, Edward R. Scheffer ; Mohyuddin, Ghulam Rehman ; Chakraborty, Rajshekhar ; Shah, Darshi ; Kelkar, Amar H. ; Swaminathan, Srivatsan ; Shah, Veer ; Mainou, Maria ; Shah, Karan ; Goodman, Aaron

01 Oct 2026·PATHOLOGY RESEARCH AND PRACTICE

Deubiquitinases in lung cancer: Oncogenic mechanisms, metabolic reprogramming, immune evasion, and therapeutic targeting

Review

Author: Guo, Jun ; Wang, Yi ; Shi, Shujing ; Yan, Weifeng

Lung cancer, encompassing lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LSCC), and small cell lung cancer (SCLC), remains the leading cause of cancer-related mortality worldwide, with adaptive resistance to targeted therapies and immune checkpoint blockade limiting durable responses. Deubiquitinases (DUBs), proteases that remove ubiquitin marks and antagonize proteasomal degradation, are increasingly recognized as context-dependent regulators of oncogenic protein stability, metabolic adaptation, immune evasion, and therapy resistance in lung cancer. Here, we synthesize preclinical evidence on a human DUB family within a subtype-aware framework. In KRAS-mutant non-small cell lung cancer (NSCLC), USP7, USP25, and OTUB1 sustain mutant KRAS abundance and MAPK output through complementary catalytic and scaffold mechanisms, whereas USP13 drives β-catenin-dependent epithelial-mesenchymal transition. In LSCC, USP28 stabilizes c-MYC, ΔNp63, and SREBP2; in LUAD, USP22 emerges as an integrative node coupling proliferation, EZH2-mediated MHC-I silencing, PD-L1 stabilization, and ferroptosis resistance; and in SCLC, USP1 mediates NK-cell evasion and MAST1-dependent cisplatin resistance, whereas USP13 sustains FASN-dependent cancer stem cell states. Multiple DUBs converge on glycolysis, ferroptosis defense, tumor-associated macrophage polarization, PD-L1/B7-H4 stability, and chemo-, targeted-, and radio-resistance programs. Therapeutic strategies are evolving from small-molecule inhibitors (GNE-6776, AZ1, and SJB2-043) to OTUB1-recruiting deubiquitinase-targeting chimeras (DUBTACs), DCAF-based PROTACs, and repurposed agents (rolapitant, ixazomib, and chidamide). Most evidence remains preclinical; substrate redundancy, validated biomarkers, and selectivity challenges must be addressed before DUB-directed strategies can be translated into biomarker-stratified combination therapies.

News (Medical) associated with Ixazomib citrate

08 Sep 2026

·www.biospace.com

Flare Therapeutics Appoints Peter Lebowitz, MD, PhD, to Board of Directors and Brian DeSchuytner as Chief Financial Officer and Chief Business Officer

- Addition of industry leader Dr. Peter Lebowitz strengthens the Board with deep oncology-focused drug development expertise - Brian DeSchuytner brings finance, business development, strategy, commercial and operations expertise to support company growth following prioritization of prostate cancer programs CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover and develop transformative therapies for prostate cancer, today announced the appointments of Peter Lebowitz, MD, PhD, to its Board of Directors and Brian DeSchuytner as Chief Financial Officer and Chief Business Officer. “We're excited to welcome Peter to our Board. He is a highly accomplished, world-class oncology drug developer and industry leader, with a track record of identifying and delivering transformational medicines and building highly productive teams. His expertise will be invaluable as we work to advance our AR(ON) degrader, FX-111, and our AR(ON) RIPTAC program to address the needs of patients living with prostate cancer,” said Anna Protopapas, Chief Executive Officer. "We're also thrilled to have Brian join Flare Therapeutics at this pivotal moment in our growth. His broad executive leadership experience across finance, business development, strategy, commercial and operations is well-suited to advance our financial and business strategy toward key value-creating milestones.” ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Appointment of Peter Lebowitz, MD, PhD, to Board of Directors Peter Lebowitz, MD, PhD, is Chief Executive Officer and Chief Medical Officer at Third Arc Bio. Prior to Third Arc Bio, Peter served as the Global Head of Oncology R&D for Johnson & Johnson (J&J) overseeing an end-to-end research and development organization that delivered 13 new drugs to market with over 60 approvals. Over his career, Peter has delivered multiple first and best-in-class transformational medicines, including ZYTIGA ® , IMBRUVICA ® , DARZALEX ® , DARZALEX FASPRO ® , ERLEADA ® , RYBREVANT ® , LAZCLUZE ® , CARVYKTI ® , TECVAYLI ® , TALVEY ® , TAFINLAR ® , and MEKINIST ® . Peter’s innovative approach to drug development resulted in 12 FDA Breakthrough Therapy Designations and 38 New England Journal of Medicine publications for J&J medicines. These achievements underscore his ability to push the boundaries of science and deliver life-changing therapies to patients. Prior to J&J, Peter also held multiple leadership roles at GlaxoSmithKline (GSK) including Vice President, Global Head of Oncology Early Clinical Development and Vice President and Medical Development Leader in Late Development. In these roles, he successfully filed 10 Investigational New Drug applications and played a leading role in taking two medicines from early discovery through global registration trials by setting a new benchmark with a “novel-novel” drug combination approach. Peter now also serves as a CEO partner at Omega Funds, a leading life science investment firm, and as a board director at Neomorph and BridgeBio Oncology Therapeutics. After earning his BA in chemistry from Harvard University, Peter earned his MD and PhD in cell and molecular biology from the University of Pennsylvania and completed his training in internal medicine and oncology at Duke University and the National Cancer Institute. "FlareTx’s AR(ON)-targeting degrader, FX-111, and AR(ON) RIPTAC are highly differentiated and have the potential to address key limitations of current prostate cancer therapies," said Dr. Lebowitz. “I am greatly impressed with the rigor and strength of the scientific evidence, and I am excited to join the Board and support the team as they advance these programs.” Appointment of Brian DeSchuytner as Chief Financial Officer and Chief Business Officer ezstandalone.cmd.push(function () { ezstandalone.showAds(132); }); Most recently, Mr. DeSchuytner was the Chief Financial Officer and Chief Operating Officer at Mersana Therapeutics, where he raised significant capital and led impactful business development collaborations with J&J, GSK, and Merck KGaA, culminating in the sale of the company to Day One Biopharmaceuticals. Prior to Mersana, he was Vice President responsible for ZEJULA ® (niraparib) commercialization at TESARO. Previously, Mr. DeSchuytner held increasingly senior roles in corporate development and in commercial at Millennium: The Takeda Oncology Company including serving as a Vice President and Global Brand Head responsible for the global launch of NINLARO ® (ixazomib). He started his career in the life sciences practice of L.E.K. Consulting. He holds an MBA from the Wharton School at the University of Pennsylvania and a BA from Dartmouth College. "Despite the introduction of novel androgen receptor pathway inhibitors and new targeted therapies, prostate cancer is a devastating disease and metastatic prostate cancer remains incurable. Targeting AR(ON) offers the potential to overcome key vulnerabilities of conventional therapies that target AR(OFF) and has broad potential across prostate cancer at all stages,” said Mr. DeSchuytner. “I look forward to partnering with Anna and the rest of the Flare Therapeutics team to demonstrate the value of our molecules and improve outcomes for patients living with prostate cancer.” Daphne Karydas, who served as President and Chief Financial Officer since October 2021, has decided to pursue other opportunities. Ms. Karydas will serve as an advisor to the Company, to support a smooth transition. “On behalf of the Board of Directors, our leadership and the entire Flare Therapeutics team, I also want to thank Daphne for her many contributions,” continued Ms. Protopapas. “Daphne was instrumental in growing and scaling the company to where we are today, including securing significant financing and executing key strategic partnerships. We wish her all the best in her new role.” ezstandalone.cmd.push(function () { ezstandalone.showAds(133); }); About Flare Therapeutics Inc. Flare Therapeutics is a clinical-stage biotechnology company drugging transcription factors to fully unlock the therapeutic potential of this previously elusive target class. The company’s discovery platform has generated a rich development portfolio which is currently focused on advancing transformative AR(ON)-targeting therapies for prostate cancer. For more information, please visit and follow us on LinkedIn . Contacts: Investors Sarah McCabe investorrelations@flaretx.com Media media@flaretx.com ezstandalone.cmd.push(function () { ezstandalone.showAds(134); });

Executive ChangeBreakthrough Therapy

31 Aug 2026

·www.fiercepharma.com

Takeda bolsters blood cancer portfolio with FDA nod for Mimrylo in polycythemia vera

The FDA has approved Takeda’s Mimrylo (rusfertide) for polycythemia vera, introducing a new mechanism of action to the nonmalignant rare blood cancer and handing CEO Julie Kim another major regulatory win since taking the helm. A form of myeloproliferative neoplasm, polycythemia vera (PV) causes the bone marrow to make too many red blood cells, which can result in life-threatening cardiovascular events, such as stroke and heart attack. Mimrylo offers a new approach to curtailing the overproduction of red blood cells; it’s the first drug for PV that mimics hepcidin, a hormone that naturally regulates iron in the body. By limiting the iron being released into the bloodstream, Mimrylo essentially starves excess production of new red blood cells. To keep the hematocrit level—the percentage of red blood cells in one’s blood—below the safe threshold of 45%, existing first-line treatment for PV includes withdrawing blood (known as phlebotomy), hydroxyurea and interferons, and Incyte’s JAK inhibitor, Jakafi, is also available as a second-line option. “People living with polycythemia vera have long faced the challenge of managing a chronic blood disorder with frequent blood draws to help address the consequences of the red blood cell overproduction,” Tanya Wroblewski, M.D., director of the division of nonmalignant hematology within the FDA’s Center for Drug Evaluation and Research, said in an Aug. 28 statement. “Today’s approval of Mimrylo offers a new, first-in-class option that has the potential to meaningfully reduce patient burden.” PV affects approximately 90,000 people in the U.S., and roughly 78% of patients don’t have hematocrit level under control with existing standard treatment, according to Takeda. Mimrylo proved its worth in the phase 3 Verify study. The double-blind trial enrolled 293 patients with uncontrolled hematocrit and randomized them to receive either a once-weekly subcutaneous injection of Mimrylo or placebo over 32 weeks. Between weeks 20 and 32 of the study, significantly more patients in the Mimrylo group improved to become not eligible for phlebotomy compared with those who took placebo. The percentages were 76.9% and 32.9%, respectively. Besides hematocrit control, Mimrylo patients also saw a reduction in the number of phlebotomy sessions and statistically significant improvement in fatigue compared with placebo. The drug was generally well-tolerated, as the most common treatment-emergent adverse events for the drug were injection site reactions and anemia. The trial is continuing into an open-label portion, which covers weeks 32 to 52 of treatment. Mimrylo marks the second FDA new drug approval that Takeda has secured since CEO Julie Kim officially took the reins in June 2026. In another first-in-class nod, the company’s orexin type 2 receptor agonist Orzeyful earned an FDA green light for narcolepsy type 1 earlier this month.\ “The approval of Mimrylo underscores the strength of Takeda’s late-stage pipeline and our focus on developing genuinely differentiated therapies for patients who are urgently waiting for new options,” Kim said in an Aug. 28 statement. “We are at an important inflection point as we prepare to deliver three new medicines, which have the potential to drive our future growth and are a reflection of our commitment to advancing innovation that doesn’t just add to the treatment landscape, but reshapes it.” The third new product Kim mentioned is the oral TYK 2 inhibitor zasocitinib , a potential competitor to Bristol Myers Squibb’s Sotyktu. Takeda is aiming to launch the drug in the U.S. for psoriasis in the first half of 2027. The Japanese pharma hopes the three new drugs could help it shake off some generic erosion to its top line. With Mimrylo’s launch, Takeda plans to draw on its existing expertise in hematology. The company already boasts a strong portfolio in blood disorders, including multiple myeloma drugs Velcade and Ninlaro, leukemia med Iclusig and Pfizer-partnered antibody-drug conjugate Adcetris. During Takeda’s recent earnings call in July, Kim flagged “a sense of inertia” among doctors in their treatment of PV, as they view the patients as “good cancer patients.” “So it’s a lot of education we need to do to help shine a light on the burden that PV patients have,” she said. Mimrylo was originally developed by Protagonist Therapeutics. Takeda paid the biotech $300 million upfront in 2024 to gain certain rights to the drug before buying its partner out earlier this year. The Japanese pharma now holds sole responsibility for commercializing Mimrylo globally. Before Friday’s approval, Jefferies analysts projected Mimrylo peak sales at roughly $2 billion. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultDrug ApprovalAcquisition

15 Jul 2026

·allsci.com

SHY Therapeutics begins first-in-human trial of novel 19S proteasome inhibitor SHY-ONC6

New York-based biotech SHY Therapeutics has initiated a Phase I first-in-human (FIH) trial of SHY-ONC6, a novel proteasome inhibitor targeting the 19S regulatory particle of the 26S proteasome, in patients with advanced or metastatic solid tumors. The multicenter study, registered as NCT07705334, enrolled its first patient on June 29, 2026, and is recruiting at sites in Denver, Houston, and San Antonio. The asset represents a mechanistic departure from approved proteasome inhibitors, which target the 20S catalytic core rather than the 19S regulatory particle. The Phase I study consists of two parts: a dose-escalation phase (Phase Ia) using accelerated titration and a Bayesian optimal interval design to identify the maximum tolerated dose, followed by a dose-expansion phase (Phase Ib) in disease-specific cohorts. SHY-ONC6 is administered orally once daily in 21-day cycles. The trial plans to enroll approximately 30 patients aged 18 years or older with advanced or metastatic solid tumors—including triple-negative breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, mesothelioma, pancreatic cancer, prostate cancer, and soft tissue sarcoma—whose disease has progressed on, or who are intolerant to, standard therapies. Primary endpoints include determination of the maximum tolerated dose and recommended Phase II dose, as well as assessments of dose-limiting toxicities and adverse events. Secondary endpoints include objective response rate, duration of response, progression-free survival, overall survival, and pharmacokinetic parameters such as area under the plasma concentration-time curve, maximum plasma concentration, and elimination half-life. The trial is expected to complete in May 2028. Proteasome inhibition is an established therapeutic strategy in oncology, particularly for hematologic malignancies. Approved proteasome inhibitors—including bortezomib (Velcade), carfilzomib (Kyprolis), and ixazomib (Ninlaro)—target the 20S catalytic core of the 26S proteasome, preventing the degradation of ubiquitinated proteins. The resulting accumulation of damaged and misfolded proteins triggers proteotoxic stress and apoptosis in cancer cells, particularly multiple myeloma and certain lymphomas, which are highly dependent on the proteasome to maintain protein homeostasis. While these agents have transformed treatment for blood cancers, their activity in solid tumors has been more limited due to a combination of biological resistance and dose-limiting toxicities. SHY-ONC6 takes a different approach by targeting the 19S regulatory particle, which sits upstream of the 20S catalytic core and is responsible for recognizing, unfolding, and delivering ubiquitinated proteins for degradation. The drug selectively inhibits AAA+ ATPase subunits within the 19S complex, aiming to disrupt proteasome function at an earlier stage than existing therapies. Researchers have proposed that targeting the 19S regulatory particle could overcome some mechanisms of resistance to 20S inhibitors and produce a distinct anti-tumor profile, although this approach remains experimental and has yet to be validated in clinical studies. The company has not disclosed any partnerships or external funding related to the SHY-ONC6 program. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Phase 1

100 Deals associated with Ixazomib citrate

External Link

KEGG	Wiki	ATC	Drug Bank
D10131	Ixazomib citrate	L01XG03	DB09570

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Multiple Myeloma	United States	Takeda Pharmaceuticals U.S.A., Inc.	20 Nov 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Plasmacytoma	Phase 3	United States	Millennium Pharmaceuticals, Inc.	29 Nov 2016
Spondylocarpotarsal Synostosis	Phase 3	United States	Millennium Pharmaceuticals, Inc.	17 Mar 2015
Spondylocarpotarsal Synostosis	Phase 3	United States	Takeda Pharmaceutical (China) Co. Ltd.	17 Mar 2015
Spondylocarpotarsal Synostosis	Phase 3	United States	Haupt Pharma Amareg GmbH	17 Mar 2015
Spondylocarpotarsal Synostosis	Phase 3	Japan	Millennium Pharmaceuticals, Inc.	17 Mar 2015
Spondylocarpotarsal Synostosis	Phase 3	Japan	Takeda Pharmaceutical (China) Co. Ltd.	17 Mar 2015
Spondylocarpotarsal Synostosis	Phase 3	Japan	Haupt Pharma Amareg GmbH	17 Mar 2015
Spondylocarpotarsal Synostosis	Phase 3	Argentina	Millennium Pharmaceuticals, Inc.	17 Mar 2015
Spondylocarpotarsal Synostosis	Phase 3	Argentina	Haupt Pharma Amareg GmbH	17 Mar 2015
Spondylocarpotarsal Synostosis	Phase 3	Argentina	Takeda Pharmaceutical (China) Co. Ltd.	17 Mar 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


IMS2026	Not Applicable	Multiple Myeloma	202	Ixazomib-based regimens	srtwpnwwis(tpyqwrlfjg) = hematologic toxicities (9.90% in ixazomib-based vs. 40.59% in the comparator cohort), peripheral neuropathy (0 vs. 15.84%), rash (0 vs. 11.88%), diarrhea (3.96% vs. 2.97%), nausea (3.96% vs. 0) exhuttnluo (ulpgicjyzb ) View more	Positive	23 Sep 2026
				Bortezomib and/or Lenalidomide-based regimens
IMS2026	Phase 2	Multiple Myeloma First line	120	Ixazomib + Lenalidomide	iksoujthes(tlclcmenvv) = 95% of the patients with sustained (two negative samples every 12 months) NGF-MRD negativity were progression-free at 2 years on maintenance. tqagzgfcnp (dfpmbjwvgg ) View more	Positive	23 Sep 2026
				Lenalidomide
PrE0404 (Pubmed \| Clin Lymphoma Myeloma Leuk)	Phase 1/2	Mantle cell lymphoma refractory	35	Ibrutinib 560 mgIxazomib 4 mg mg + Ibrutinib 560 mgIxazomib 4 mg	chvbbwpdud(xyiasgufxf) = tsuunyumch dgmiwlaiuo (nlbivadyas ) View more	Negative	01 Jul 2026
NCT02516423 (CTgov)	Phase 3	Plasmacytoma	11	Lenalidomide+ixazomib+zoledronic acid+dexamethasone (Ixazomib + Lenalidomide + Dexamethasone + Zoledronic Acid)	blhlsabwrx = kphjaqbrtf fbytvnzilc (pkxbxlvocz, bntpssnqty - rwxdqrrdfy) View more	-	30 Jun 2026
				zoledronic acid (Zoledronic Acid)	blhlsabwrx = ixbfmswjds fbytvnzilc (pkxbxlvocz, nzktfpvwym - alibxulpan) View more
EHA2026	Not Applicable	Multiple Myeloma	113	Ixazomib-based regimens	jqzpdexkts(odgdwwpscx) = Among those switching due to intolerance (n=17), 10/17 (58.8%) continued therapy, with no discontinuations attributed to adverse events lupecdpolh (gktsudrnpo )	Positive	12 May 2026
				Ixazomib-based regimens (High-risk)
EHA2026	Not Applicable	Multiple Myeloma First line	12,905	IXAZOMIB-based triplet regimens	okcdoplmvf(pmegpmhgfy) = ttsdzadtry fothqjdinj (oymmlzhxvv, 5.6 - 13.1) View more	Positive	12 May 2026
				BORTEZOMIB-based triplet regimens	okcdoplmvf(pmegpmhgfy) = sobpkzyalv fothqjdinj (oymmlzhxvv, 3.7 - 11.2) View more
EHA2026	Not Applicable	Multiple Myeloma Maintenance	47	Ixazomib-based maintenance	gdyblrcizq(ouilmnkdjs) = The most common adverse events were hematologic toxicities (neutropenia: 11%, grade 3: 0%; thrombocytopenia: 4%, grade 3: 2%; anemia: 40%, grade 3: 0%), gastrointestinal events (diarrhea: 6.4%, grade 3: 2.1%; nausea: 2.1%, grade 3: 0%), rash (2.1%, grade 3), fatigue (2.1%, grade 2), upper respiratory tract infection (2.1%, grade 2), heart failure (2.1%, grade 2), and peripheral neuropathy (4.3%, grade 2). No treatment discontinuations due to adverse events were reported. fgoigwjcoe (fgzwcsoxuf )	Positive	12 May 2026
NCT05722405 (MPACT, EHA2026)	Phase 2	Multiple Myeloma Maintenance	41	IXAZOMIB + REDUCED-DOSE LENALIDOMIDE	gfohqkidwk(wlkxptwhhl) = dpqzlwpzxw mfuxntmvss (tbvrikrkkp, 18.2 - 53.8)	Positive	12 May 2026
				IXAZOMIB	gfohqkidwk(wlkxptwhhl) = jzipkzzpys mfuxntmvss (tbvrikrkkp, 10.7 - 27.3)
EHA2026	Not Applicable	Refractory Multiple Myeloma	152	IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE	qccztzyxvg(bsvhhrwevx) = wjmjrvlrxh wlvbmhayud (ytocnlhene ) View more	Positive	12 May 2026
				DARATUMUMAB-LENALIDOMIDE-DEXAMETHASONE	gaaylkneph(xlccfnprtn) = gqcahyegsc zhkvchihkl (eqdbejedzc )
EHA2026	Not Applicable	Relapse multiple myeloma	24	Ixazomib, lenalidomide, and dexamethasone (IRd) (3 prior lines)	suzihpugyz(flkhlpvtyh) = iesyiheqrw porthyxykv (waqgkegflx )	Positive	12 May 2026
				Ixazomib, lenalidomide, and dexamethasone (IRd) (4-6 prior lines)	suzihpugyz(flkhlpvtyh) = wsvklffhpw porthyxykv (waqgkegflx )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis